Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site

Ronald (Ron) Rosenfeld, D. M. Wilson, L. A. Dollar, A. Bennett, R. L. Hintz

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

The authors have investigated the effects on carbohydrate metabolism of human GH produced by recombinant DNA technology (methionyl-hGH) compared with pituitary hGH. Twelve normal adult male subjects received four daily im injections of either methionyl-hGH or pituitary hGH in a double blind, crossover study. Oral glucose tolerance tests and assays of insulin binding to peripheral monocytes were performed before the initial administration and 12 h after the fourth injection of both hGH preparations. Both methionyl-hGH and pituitary hGH resulted in significant carbohydrate intolerance, with a rise in fasting plasma glucose from 96.6 ± 2.9 to 105.9 ± 3.0 mg/ml (mean ± SEM) after pituitary hGH and from 96.2 ± 1.5 to 107.5 ± 3.3 mg/dl after methionyl-hGH (P <0.01). The area under the glucose tolerance curve increased by 34% after pituitary hGH and by 37% after methionyl-hGH. With both hGH preparations, carbohydrate intolerance was associated with marked hyperinsulinemia, with a rise in fasting plasma insulin levels from 9.4 ± 1.2 to 33.2 ± 7.8 μU/ml after pituitary hGH and from 7.4 ± 1.1 to 45.8 ± 11.1 μU/ml after methionyl-hGH (P <0.01). The integrated plasma insulin levels during the oral glucose tolerance test tripled after both hGH preparations. The pronounced insulin resistance could not be attributed to an alteration in insulin receptor concentrations. Both hGH preparations were associated with small reductions in insulin binding to monocytes at tracer concentrations, but the decline in binding was not statistically significant. The calculated binding sites per cell and Kē were not significantly altered by hGH administration. It is concluded that methionyl-hGH and pituitary hGH are indistinguishable in their ability to induce insulin-resistant carbohydrate intolerance. This decrease in insulin sensitivity cannot be attributed to an alteration in insulin binding, and presumably represents a postreceptor defect in insulin action.

Original languageEnglish (US)
Pages (from-to)1033-1038
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume54
Issue number5
StatePublished - 1982
Externally publishedYes

Fingerprint

Recombinant DNA
Human Growth Hormone
Hormones
Growth Hormone
Insulin Resistance
Insulin
Glucose Tolerance Test
Glucose
Monocytes
Carbohydrates
Fasting
Plasmas
Injections
Aptitude
Insulin Receptor
Carbohydrate Metabolism
Hyperinsulinism
Genetic engineering
Double-Blind Method
Cross-Over Studies

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site. / Rosenfeld, Ronald (Ron); Wilson, D. M.; Dollar, L. A.; Bennett, A.; Hintz, R. L.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 54, No. 5, 1982, p. 1033-1038.

Research output: Contribution to journalArticle

Rosenfeld, Ronald (Ron) ; Wilson, D. M. ; Dollar, L. A. ; Bennett, A. ; Hintz, R. L. / Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site. In: Journal of Clinical Endocrinology and Metabolism. 1982 ; Vol. 54, No. 5. pp. 1033-1038.
@article{818d9cf864d9465fbce287cbf72a7354,
title = "Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site",
abstract = "The authors have investigated the effects on carbohydrate metabolism of human GH produced by recombinant DNA technology (methionyl-hGH) compared with pituitary hGH. Twelve normal adult male subjects received four daily im injections of either methionyl-hGH or pituitary hGH in a double blind, crossover study. Oral glucose tolerance tests and assays of insulin binding to peripheral monocytes were performed before the initial administration and 12 h after the fourth injection of both hGH preparations. Both methionyl-hGH and pituitary hGH resulted in significant carbohydrate intolerance, with a rise in fasting plasma glucose from 96.6 ± 2.9 to 105.9 ± 3.0 mg/ml (mean ± SEM) after pituitary hGH and from 96.2 ± 1.5 to 107.5 ± 3.3 mg/dl after methionyl-hGH (P <0.01). The area under the glucose tolerance curve increased by 34{\%} after pituitary hGH and by 37{\%} after methionyl-hGH. With both hGH preparations, carbohydrate intolerance was associated with marked hyperinsulinemia, with a rise in fasting plasma insulin levels from 9.4 ± 1.2 to 33.2 ± 7.8 μU/ml after pituitary hGH and from 7.4 ± 1.1 to 45.8 ± 11.1 μU/ml after methionyl-hGH (P <0.01). The integrated plasma insulin levels during the oral glucose tolerance test tripled after both hGH preparations. The pronounced insulin resistance could not be attributed to an alteration in insulin receptor concentrations. Both hGH preparations were associated with small reductions in insulin binding to monocytes at tracer concentrations, but the decline in binding was not statistically significant. The calculated binding sites per cell and Kē were not significantly altered by hGH administration. It is concluded that methionyl-hGH and pituitary hGH are indistinguishable in their ability to induce insulin-resistant carbohydrate intolerance. This decrease in insulin sensitivity cannot be attributed to an alteration in insulin binding, and presumably represents a postreceptor defect in insulin action.",
author = "Rosenfeld, {Ronald (Ron)} and Wilson, {D. M.} and Dollar, {L. A.} and A. Bennett and Hintz, {R. L.}",
year = "1982",
language = "English (US)",
volume = "54",
pages = "1033--1038",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site

AU - Rosenfeld, Ronald (Ron)

AU - Wilson, D. M.

AU - Dollar, L. A.

AU - Bennett, A.

AU - Hintz, R. L.

PY - 1982

Y1 - 1982

N2 - The authors have investigated the effects on carbohydrate metabolism of human GH produced by recombinant DNA technology (methionyl-hGH) compared with pituitary hGH. Twelve normal adult male subjects received four daily im injections of either methionyl-hGH or pituitary hGH in a double blind, crossover study. Oral glucose tolerance tests and assays of insulin binding to peripheral monocytes were performed before the initial administration and 12 h after the fourth injection of both hGH preparations. Both methionyl-hGH and pituitary hGH resulted in significant carbohydrate intolerance, with a rise in fasting plasma glucose from 96.6 ± 2.9 to 105.9 ± 3.0 mg/ml (mean ± SEM) after pituitary hGH and from 96.2 ± 1.5 to 107.5 ± 3.3 mg/dl after methionyl-hGH (P <0.01). The area under the glucose tolerance curve increased by 34% after pituitary hGH and by 37% after methionyl-hGH. With both hGH preparations, carbohydrate intolerance was associated with marked hyperinsulinemia, with a rise in fasting plasma insulin levels from 9.4 ± 1.2 to 33.2 ± 7.8 μU/ml after pituitary hGH and from 7.4 ± 1.1 to 45.8 ± 11.1 μU/ml after methionyl-hGH (P <0.01). The integrated plasma insulin levels during the oral glucose tolerance test tripled after both hGH preparations. The pronounced insulin resistance could not be attributed to an alteration in insulin receptor concentrations. Both hGH preparations were associated with small reductions in insulin binding to monocytes at tracer concentrations, but the decline in binding was not statistically significant. The calculated binding sites per cell and Kē were not significantly altered by hGH administration. It is concluded that methionyl-hGH and pituitary hGH are indistinguishable in their ability to induce insulin-resistant carbohydrate intolerance. This decrease in insulin sensitivity cannot be attributed to an alteration in insulin binding, and presumably represents a postreceptor defect in insulin action.

AB - The authors have investigated the effects on carbohydrate metabolism of human GH produced by recombinant DNA technology (methionyl-hGH) compared with pituitary hGH. Twelve normal adult male subjects received four daily im injections of either methionyl-hGH or pituitary hGH in a double blind, crossover study. Oral glucose tolerance tests and assays of insulin binding to peripheral monocytes were performed before the initial administration and 12 h after the fourth injection of both hGH preparations. Both methionyl-hGH and pituitary hGH resulted in significant carbohydrate intolerance, with a rise in fasting plasma glucose from 96.6 ± 2.9 to 105.9 ± 3.0 mg/ml (mean ± SEM) after pituitary hGH and from 96.2 ± 1.5 to 107.5 ± 3.3 mg/dl after methionyl-hGH (P <0.01). The area under the glucose tolerance curve increased by 34% after pituitary hGH and by 37% after methionyl-hGH. With both hGH preparations, carbohydrate intolerance was associated with marked hyperinsulinemia, with a rise in fasting plasma insulin levels from 9.4 ± 1.2 to 33.2 ± 7.8 μU/ml after pituitary hGH and from 7.4 ± 1.1 to 45.8 ± 11.1 μU/ml after methionyl-hGH (P <0.01). The integrated plasma insulin levels during the oral glucose tolerance test tripled after both hGH preparations. The pronounced insulin resistance could not be attributed to an alteration in insulin receptor concentrations. Both hGH preparations were associated with small reductions in insulin binding to monocytes at tracer concentrations, but the decline in binding was not statistically significant. The calculated binding sites per cell and Kē were not significantly altered by hGH administration. It is concluded that methionyl-hGH and pituitary hGH are indistinguishable in their ability to induce insulin-resistant carbohydrate intolerance. This decrease in insulin sensitivity cannot be attributed to an alteration in insulin binding, and presumably represents a postreceptor defect in insulin action.

UR - http://www.scopus.com/inward/record.url?scp=0020402108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020402108&partnerID=8YFLogxK

M3 - Article

C2 - 7037819

AN - SCOPUS:0020402108

VL - 54

SP - 1033

EP - 1038

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -